Compare testosterone gels, injections and other TRT formulations by delivery, practical risks, fertility considerations and monitoring needs.
Daily topical testosterone and testosterone injections offer different ways to deliver replacement hormone, with the clinical choice shaped by absorption, level fluctuations and the demands of safe follow-up.
This article is for informational purposes and is not medical advice. Diagnosis and decisions about testosterone treatment belong with a qualified clinician who can assess the individual’s circumstances.
Topical testosterone replacement therapy, or TRT, delivers testosterone through the skin. The European Association of Urology’s Male Hypogonadism guideline describes gels and patches as replacement options with distinct delivery characteristics. Their medical use sits within treatment for compatible symptoms and confirmed biochemical testosterone deficiency.
According to the EAU guideline, testosterone gel is absorbed through the skin and creates a reservoir that delivers hormone over about 24 hours after daily application. This makes daily use part of the treatment’s practical demands rather than an occasional task.
The central trade-off is skin-based delivery. The guideline notes that testosterone can transfer to another person through close skin contact. That consideration belongs in the formulation discussion because treatment affects more than the person’s schedule or preference for avoiding injections.
Gel also introduces a particular laboratory concern. The EAU warns that contamination at the blood-draw site can produce a falsely high testosterone result. Clinicians therefore need to consider both the timing of the sample and possible contamination when interpreting monitoring results.
For shared decision-making, gel raises concrete questions: whether daily application fits the patient’s circumstances and how transfer precautions will be managed. Those questions help turn a general preference for topical treatment into a discussion of its actual demands.
The EAU describes testosterone patches as providing steady-state levels without fluctuation. They also require daily use and can cause skin irritation. A patch therefore changes the practical trade-offs within topical therapy rather than removing them.
The relevant distinction is between the delivery pattern and the skin’s response to the preparation. A patient’s preference for a patch needs to be weighed alongside tolerability and availability, as the guideline recommends for formulation selection generally.
Injectable TRT delivers replacement testosterone by injection rather than absorption through the skin. The EAU distinguishes shorter-acting preparations from long-acting testosterone undecanoate. These should not be treated as a single option because their delivery patterns and practical disadvantages differ.
The EAU describes testosterone enanthate and cypionate as lower-cost options that require repeat injections. It also lists fluctuations in circulating testosterone and a relative risk of polycythaemia among their disadvantages. Polycythaemia means an increased concentration of red blood cells.
This creates a different balance from daily topical treatment. Repeat injections replace the daily application task, but circulating testosterone may fluctuate. Injection comfort and the pattern of delivery become relevant parts of the discussion.
The guideline also reports that raised haematocrit is more frequently associated with injectable than topical formulations. Haematocrit reflects the proportion of blood occupied by red blood cells. This route-related finding is a reason to discuss monitoring, not a prediction that every person using injections will develop the same problem.
The EAU describes long-acting testosterone undecanoate as a less-frequent injection that can maintain stable testosterone levels. Clinicians can adjust the interval using a pre-injection testosterone measurement after several injections. Less-frequent administration therefore still involves ongoing assessment.
Its longer duration also creates a trade-off: a long-acting depot cannot be withdrawn quickly if an adverse effect occurs. The guideline lists injection-site pain as another disadvantage. Convenience and the ability to respond promptly to a problem must be considered together.
The EAU recommends choosing a testosterone preparation jointly with the patient. That decision considers clinical circumstances and availability alongside patient needs and expectations. The preparation’s relative risks and benefits remain part of the same discussion.
For topical therapy, the conversation may centre on daily use and skin-related issues. For injections, it may centre on repeat administration and the pattern of circulating testosterone. Neither conversation is complete without considering follow-up.
A 2026 American Academy of Family Physicians commentary says no available formulation is clearly superior. It summarizes a meta-analysis as finding no difference among formulations, but notes that most studies in that analysis evaluated only one formulation, typically a patch. That evidence does not establish a robust head-to-head ranking of every route.
The practical implication is to compare supported delivery characteristics rather than assume a universal winner. A steady delivery pattern is one consideration. It must be weighed with tolerability and monitoring needs rather than treated as proof of better overall effectiveness.
Both topical and injectable TRT supply testosterone from outside the body. The EAU states that exogenous testosterone suppresses gonadotropin secretion and sperm production. It advises against testosterone therapy in men seeking fertility.
Choosing a different delivery route does not resolve that endocrine effect. Current or future fertility plans therefore belong in the clinical discussion before formulation preferences. This is a treatment-context issue rather than a reason to select gel over injections or injections over gel.
The formulation decision follows a broader assessment of symptoms and hormone findings. According to the EAU guideline, diagnosis requires compatible symptoms and low morning testosterone on at least two occasions. Testing should use a reliable assay under fasting conditions.
For readers still investigating symptoms, understanding how symptom concerns fit with blood testing is a useful starting point. Comparing delivery routes should not substitute for determining whether testosterone treatment is appropriate.
The EAU recommends measuring testosterone two to four hours after gel application. For long-acting testosterone undecanoate injections, it describes using the pre-injection level to guide interval adjustment. These samples answer different monitoring questions because they are collected at different points in the delivery cycle.
Timing is therefore part of interpretation rather than a detail added after the result arrives. A useful question for the clinician is how the planned sample relates to the proposed preparation. The answer should come from the treating team rather than a reader changing application or injection timing independently.
This also illustrates why hormone results need clinical context. The formulation and sampling conditions help determine what a testosterone measurement means during treatment.
The EAU’s follow-up schedule includes testosterone and haematocrit measurements at baseline. It then recommends checks at three, six and 12 months, followed by annual monitoring. Follow-up is adapted to clinical circumstances.
Because raised haematocrit is a recognized adverse effect, its monitoring belongs in the initial formulation discussion. The guideline describes clinician-led adjustment or withdrawal when haematocrit becomes excessive. Decisions about changing or stopping therapy require qualified care rather than self-directed changes based on a laboratory result.
The EAU describes testosterone implants as long-lasting preparations that provide constant serum levels. Its preparation table states that they can last up to six months. Pellets are available in only a limited number of countries.
Their practical advantage is longer duration, but placement is invasive. The guideline lists extrusion and site infection among the risks. The comparison therefore shifts from daily application or repeat injections toward a procedure and its local complications.
The EAU distinguishes older oral testosterone undecanoate preparations from newer self-emulsifying capsules. Absorption of the older preparations depends strongly on dietary fat, and they must be taken with meals. The newer capsules have improved oral availability.
The guideline also notes that newer oral testosterone undecanoate formulations have been associated with a mild increase in blood pressure. It reports that the FDA required a black-box warning for this risk. Meal-related absorption and blood-pressure considerations both belong in a discussion of oral treatment.
The EAU describes buccal testosterone as a tablet applied to the upper gum twice daily. Possible disadvantages include local oral irritation and an unpleasant taste. This route changes the application site but retains recurring daily treatment demands.
Intranasal gel requires two or three applications a day, according to the guideline. Nasal irritation and frequent application are listed as disadvantages. Avoiding secondary transfer is listed as an advantage.
These options show why convenience needs a specific definition. Avoiding injections may matter to one patient, while the frequency of daily application may matter more to another. The EAU’s shared-decision approach accommodates those differences without turning them into a product ranking.
The research supports bringing these questions to a qualified clinician:
These questions keep the choice connected to clinical care. For broader context, understanding the distinction between regulated treatments and other testosterone products can also help separate a medical formulation discussion from product marketing.
Topical and injectable testosterone are delivery choices within a broader clinical decision that combines diagnosis, fertility considerations, practical demands and ongoing monitoring.
A convenient testosterone formulation does not settle questions about symptoms or their cause, so Testostra separates its treatment education from personal medical advice. Its evidence-led coverage of low testosterone, testing and TRT helps men understand uncertainty about symptoms and possible causes before discussing their concerns with a qualified clinician.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra